Zelira Therapeutics Ltd
G1G
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
8
Stocks News & Analysis
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
stocks
Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch
Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.00 | 54.60 | -0.59% |
| CAC 40 | 8,278.77 | 7.63 | -0.09% |
| DAX 40 | 26,046.40 | 43.08 | 0.17% |
| Dow JONES (US) | 53,414.25 | 271.86 | -0.51% |
| FTSE 100 | 10,831.09 | 0.43 | -0.00% |
| HKSE | 25,650.87 | 437.56 | 1.74% |
| NASDAQ | 26,506.99 | 77.07 | -0.29% |
| Nikkei 225 | 65,020.94 | 806.46 | 1.26% |
| NZX 50 Index | 13,974.18 | 128.00 | 0.92% |
| S&P 500 | 7,718.60 | 29.11 | -0.38% |
| S&P/ASX 200 | 9,005.90 | 64.30 | -0.71% |
| SSE Composite Index | 3,930.12 | 11.97 | -0.30% |